The first tissue regeneration therapy for Short Bowel Syndrome (SBS). SBS is a devastating condition where the small intestine is too short to absorb sufficient nutrients to sustain a patient. It results from the surgical removal of a large portion of the small intestine due to a congenital or acquired defect. The Eclipse XL1 therapy is designed to grow 2-3x longer, healthy intestine within 2-3 weeks using an entirely mechanical, repeatable approach. The new tissue has been shown to absorb nutrients and function the same as, or better than, healthy intestinal tissue.
The Eclipse XL 1 device is an investigational product and limited by Federal law to investigational use. It is not currently available for commercial sale in the U.S. or any other region.
Eclipse Regenesis and Eclipse XL1 are registered trademarks of Eclipse Regenesis, Inc.
Company Details
- Employees
- 8
- Founded
- -
- Address
- 1440 O'brien Drive,
- Industry
- Medical Device
- Website
- http://www.eclipseregenesis.com
- HQ
- Menlo Park, California
Eclipse Regenesis Questions
Eclipse Regenesis's website is http://www.eclipseregenesis.com
Eclipse Regenesis's LinkedIn profile is https://www.linkedin.com/company/eclipseregenesis
Eclipse Regenesis has
8 employees.
View email and phone details for 8
employees at Eclipse Regenesis.
Eclipse Regenesis's industry is
Medical Device
Eclipse Regenesis's top competitors are
Enspectra Health, Inc.,
Imvaria,
Upsilon,
Raydiant Oximetry, Inc.,
Neocare Innovations,
Hy2care® Bv,
Fogarty Innovation,
Luma Vision,
Identical,
Opalgenix.
Eclipse Regenesis's categories are Medical Device
Eclipse Regenesis's founding year is 2017
